journal
MENU ▼
Read by QxMD icon Read
search

Clinical & Translational Oncology

journal
https://www.readbyqxmd.com/read/28646282/surgery-for-pancreatic-ductal-adenocarcinoma
#1
REVIEW
R Vera, L Díez, E Martín Pérez, J C Plaza, A Sanjuanbenito, A Carrato
Surgical resection is the only potentially curative option in the treatment of pancreatic ductal adenocarcinoma. Preoperative radiological imaging allows to rule out the presence of metastases. Three resectability categories are established based on the radiological findings depending on the degree of contact between the tumor and the blood vessels. Histological confirmation of malignancy is only required in cases of borderline or non-resectable tumors, prior to neoadjuvant treatment initiation. Diagnostic laparoscopy is recommended in the presence of large tumors of the body or tail and in borderline tumors to explore the possibility of resection and to apply treatment with curative intent, as well as in those cases with high level of biomarkers to rule out peritoneal involvement...
June 23, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28639051/adjuvant-treatment-for-pancreatic-ductal-carcinoma
#2
REVIEW
T Macarulla, T Fernández, M E Gallardo, O Hernando, A M López, M Hidalgo
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a very poor prognosis. Most of the patients are diagnosed in advanced stages of the disease, and 5-year survival rates in these patients remains <10%. Surgery still remains the only radical treatment option, although only 15-20% of patients are candidates for surgical resection at the time of the diagnosis. Patients who undergo radical surgery still have a limited survival rate, being the average of 23 months. Three clinical trials have shown that adjuvant chemotherapy therapy after surgery may improve survival: CONKO-1, ESPAC-3, and ESPAC-4...
June 21, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28631135/long-term-clinical-benefit-from-salvage-egfr-tyrosine-kinase-inhibitors-in-advanced-non-small-cell-lung-cancer-patients-with-egfr-wild-type-tumors
#3
F Koinis, A Voutsina, A Kalikaki, A Koutsopoulos, E Lagoudaki, E Tsakalaki, E K Dermitzaki, E Kontopodis, A G Pallis, V Georgoulias, A Kotsakis
BACKGROUND: Erlotinib has been approved for the management of NSCLC patients after failure of the first or subsequent line of chemotherapy. Although the efficacy of erlotinib is clearly associated with the presence of EGFR mutations, there is a subset of patients with EGFR wild-type (EGFRwt) tumors who impressively respond. PATIENTS AND METHODS: Patients with EGFRwt NSCLC who received salvage (≥2nd line) treatment with erlotinib for a prolonged period (>6 months), were sought from the database of the Hellenic Oncology Research Group...
June 19, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28623515/pancreatic-ductal-adenocarcinoma-metastatic-disease
#4
REVIEW
A J Muñoz Martín, J Adeva, J Martínez-Galán, J J Reina, M Hidalgo
The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called "therapeutic sequencing" has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient's characteristics...
June 16, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28623514/the-potential-roles-of-bacteria-to-improve-radiation-treatment-outcome
#5
REVIEW
E Kouhsari, A Ghadimi-Daresajini, H Abdollahi, N Amirmozafari, S R Mahdavi, S Abbasian, S H Mousavi, H F Yaseri, M Moghaderi
Many combined therapies have been proposed to enhance radiotherapy outcome, but they have several limitations. As a new feasible strategy, combination of radiotherapy with bacteria showed a significant positive impact on the tumor treatment and metastasis inhibition. Although probiotic bacteria and radiotherapy alone can be effective in the treatment of different cancers, the combination of these two therapies seems to enhance therapeutic outcome and is cost-effective. Bacterial cells can act as therapeutic/gene/drug delivery vehicles as well as theranostic agents...
June 16, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28623513/the-spine-instability-neoplastic-score-sins-in-the-assessment-of-response-to-radiotherapy-for-bone-metastases
#6
E Gallizia, G Apicella, T Cena, M Di Genesio Pagliuca, L Deantonio, M Krengli
BACKGROUND: Vertebral metastases are often causing pain and spine instability. Radiotherapy is of significant benefit for painful spine metastases but the response can be very variable. The spine instability neoplastic score (SINS) is a recent classification system for diagnosis of spinal instability caused by vertebral metastases. We analysed the degree of pain relief, the need of drug therapy and the imaging features and the SINS before and after radiotherapy. In particular, we investigated the possible correlation of spine instability defined by pre-treatment SINS with pretreatment pain and with response to radiotherapy...
June 16, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28616721/biomarkers-in-pancreatic-ductal-adenocarcinoma
#7
REVIEW
J Gallego, C López, R Pazo-Cid, F López-Ríos, A Carrato
Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease. Nomenclature for molecular subtypes of tumours is gradually gaining acceptance and there are growing expectations it will further go from the bench to the bedside. However, the clinical relevance of biomarkers in PDAC is still far behind the relevance of biomarkers in other solid tumours...
June 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28616720/quality-of-life-after-whole-brain-radiotherapy-compared-with-radiosurgery-of-the-tumor-bed-results-from-a-randomized-trial
#8
L Kepka, D Tyc-Szczepaniak, K Osowiecka, A Sprawka, B Trąbska-Kluch, B Czeremszynska
BACKGROUND: A recent randomized trial (NCT01535209) demonstrated no difference in neurocognitive function between stereotactic radiotherapy of the tumor bed (SRT-TB) and whole brain radiotherapy (WBRT) in patients with resected single brain metastasis. Patients treated with SRT-TB had lower overall survival compared with the WBRT arm. Here, we compared the health-related quality of life (HRQOL) in patients who received WBRT vs. SRT-TB. METHODS: A self-reported questionnaire was used to assess HRQOL (EORTC QLQ-C30 with the QLQ-BN20 module) before RT, 2 months after RT, and every 3 months thereafter...
June 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28612203/neoadjuvant-treatment-for-borderline-and-resectable-pancreatic-ductal-adenocarcinoma
#9
REVIEW
R Álvarez, I Alés, R Díaz, B G de Paredes, M Hidalgo
Nowadays and given the improvement in response rate with the new schemes of treatment with chemotherapy, the interest in neoadjuvant treatment for pancreatic ductal adenocarcinoma, allowing the early application of systemic therapies, has also increased. However, treatment selection fundamentally depends on decisions taken by multidisciplinary committees due to the absence of randomized trials on this indication and because the available evidence is based primarily on small studies. The present manuscript tries to establish recommendations based on the available evidence and expert opinion to correctly select the indication, the type of treatment, as well as its duration and how to correctly follow-up patients during treatment with chemotherapy...
June 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28612202/management-of-unresectable-locally-advanced-pancreatic-adenocarcinoma
#10
REVIEW
M Salgado, S Arévalo, O Hernando, A Martínez, R Yaya, M Hidalgo
The diagnosis of unresectable locally advanced pancreatic adenocarcinoma (LAPC) requires confirmation, through imaging tests, of the unfeasibility of achieving a complete surgical resection, in the absence of metastatic spread. The increase in overall survival (OS), together with an appropriate symptom management is the therapeutic target in LAPC, maintaining an acceptable quality of life and, if possible, increasing the time until the appearance of metastasis. Chemoradiation (CRT) improves OS compared to best support treatment or radiotherapy (RT) but with greater toxicity...
June 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28612201/supportive-care-in-pancreatic-ductal-adenocarcinoma
#11
REVIEW
B Laquente, A Calsina-Berna, A Carmona-Bayonas, P Jiménez-Fonseca, I Peiró, A Carrato
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with poorest prognosis and represents the third leading cause of cancer-related deaths in Western countries. Despite advances in diagnostic procedures and treatment, diagnosis is made in most cases when the disease is locally advanced or metastatic. Supportive care aims to improve symptoms, reduce hospital admission rates, and preserve quality of life. Proper symptomatic management is critical to allow administration of chemotherapy and radiotherapy...
June 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28612200/diagnosis-and-staging-of-pancreatic-ductal-adenocarcinoma
#12
REVIEW
C Guillén-Ponce, J Blázquez, I González, E de-Madaria, J Montáns, A Carrato
The management of pancreatic ductal adenocarcinoma (PDAC) is a major public health concern worldwide. Currently, most PDAC patients are diagnosed in advanced stages. The signs and symptoms of the disease, except for jaundice, are non-specific. Thus, the current challenge is to identify earlier those individuals for whom specific screening tools and specific treatments would be beneficial. On the basis of the recommendations of the group of experts of multiple medical specialties of the GALLgo Project, the patients with PDAC should be managed by a multidisciplinary team to assess the personal and family history, the best diagnostic and staging procedures and consider all important aspects for treatment decisions...
June 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28612199/mri-guided-radiotherapy-for-head-and-neck-cancer-initial-clinical-experience
#13
A M Chen, S Hsu, J Lamb, Y Yang, N Agazaryan, M L Steinberg, D A Low, M Cao
PURPOSE: To report a single-institutional experience with the use of magnetic resonance imaging (MRI)-guided radiotherapy for cancers of the head and neck. MATERIALS AND METHODS: Between October 2014 and October 2016, 18 patients with newly diagnosed cancers of the head and neck were prospectively enrolled on an institutional registry trial investigating the feasibility and efficacy of external-beam radiotherapy delivered using on-board MRI. All patients had biopsy-proven evidence of malignancy, measurable disease, and the ability to provide consent...
June 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28600675/a-novel-capillary-nano-immunoassay-for-assessing-androgen-receptor-splice-variant-7-in-plasma-correlation-with-cd133-antigen-expression-in-circulating-tumor-cells-a-pilot-study-in-prostate-cancer-patients
#14
J L García, R Lozano, I Misiewicz-Krzeminska, J Fernández-Mateos, P Krzeminski, S Alfonso, R A Marcos, R García, F Gómez-Veiga, Á Virseda, M Herrero, D Olmos, J J Cruz-Hernández
PURPOSE: Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. METHODS: Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform...
June 9, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28593335/key-points-to-optimizing-management-and-research-on-cancer-associated-thrombosis
#15
REVIEW
A Carmona-Bayonas, M Sánchez-Cánovas, J M Plasencia, A Custodio, E Martínez de Castro, J A Virizuela, F Ayala de la Peña, P Jiménez-Fonseca
Despite the fact that thromboembolism is relatively common in oncology patients and that the interrelationship between thrombotic risk and specific mechanisms of tumorigenesis has long been known, many cardinal elements of prevention and treatment remain unresolved. Among the existing knowledge gaps, the need to validate the Ay scale and compare it to the Khorana index, develop, and standardize the use of predictive biomarkers for thrombotic risk, conduct clinical trials in thromboprophylaxis adapted to thrombotic risk, evaluate the efficacy and safety of direct anticoagulants, select patients who can benefit from anticoagulants for antitumor treatment, validate the EPIPHANY study decision tree to choose patients with low-risk pulmonary embolism, and accumulate more practical experience in special situations (rethrombosis, prolonged therapy beyond 6 months, etc...
June 7, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28589434/outcome-and-toxicity-of-intensity-modulated-radiotherapy-with-simultaneous-integrated-boost-in-locally-advanced-non-small-cell-lung-cancer-patients
#16
A Fondevilla Soler, J L López-Guerra, M Dzugashvili, P Sempere Rincón, A Sautbaet, P Castañeda, J M Díaz, J M Praena-Fernandez, E Rivin Del Campo, I Azinovic
PURPOSE: The aim of this study was to assess the feasibility and treatment outcome of intensity modulated radiation therapy with simultaneous integrated boost (SIB-IMRT) in locally advanced non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: A total of 64 NSCLC patients with stage IIB (3%), IIIA (36%), and IIIB (61%) were treated with concomitant (N = 47; 73%) or sequential (N = 9; 14%) chemotherapy between February 2009 and January 2014. Eight patients (13%) received RT alone...
June 6, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28589433/overexpression-of-dishevelled-2-is-involved-in-tumor-metastasis-and-is-associated-with-poor-prognosis-in-hepatocellular-carcinoma
#17
C Zhang, C Li, X Chen, Y Zhou, B Yin, R Ni, Y Zhang, J Liu
PURPOSE: Although hepatocellular carcinoma (HCC) is one of the most common malignant tumors, its molecular mechanism is still unknown. Dishevelled 2 (Dvl2) is one of the downstream targets of non-canonical Wnt signaling, which has been demonstrated to be of great importance in the progression of cancers. Nevertheless, the expression mechanisms and physiological significance of Dvl2 in HCC remain unclear. METHODS: Western blotting and immunohistochemistry were used to measure Dvl2 protein expression in HCC and adjacent normal tissues of 101 patients...
June 6, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28589432/comparative-efficacy-and-toxicity-of-induction-chemotherapy-with-concurrent-stereotactic-body-radiotherapy-and-stereotactic-body-radiotherapy-with-subsequent-chemotherapy-in-patients-with-clinical-stage-t1-3n0m0-non-small-cell-lung-carcinoma
#18
Y Sun, Q Duan, X Chen, W Chen, X Jin, R Wu
PURPOSE: We compared the clinical efficacy and toxicity of stereotactic body radiotherapy with induction chemotherapy and concurrent radiochemotherapy vs stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma. METHODS: We retrospectively analyzed 38 patients with c-stage T1-3N0M0 non-small cell lung carcinoma who received stereotactic body radiotherapy. All patients received six cycles of chemotherapy...
June 6, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28589431/bone-marrow-fibrosis-at-diagnosis-predicts-survival-for-primary-acute-myeloid-leukemia
#19
Z Wu, R Chen, L Wu, L Zou, F Ding, M Wang, X Liu
PURPOSE: As a desmoplastic reaction, tissue fibrosis played crucial roles in solid tumor progression, chemo-resistance, and consequently heralded poor clinical outcome. Previous studies implied the effects of marrow fibrosis on prognosis for acute lymphoblastic leukemia were disputable. In this study, we aimed to investigate the potential role of bone marrow fibrosis on clinical survival in acute myeloid leukemia (AML) patients. METHODS: Bone marrow fibrosis (evaluated as reticulin fiber density, RFD) in bone marrow sections was evaluated at diagnosis via computer technology...
June 6, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28589430/slc14a1-a-novel-target-for-human-urothelial-cancer
#20
REVIEW
R Hou, X Kong, B Yang, Y Xie, G Chen
Urinary bladder cancer is the second commonly diagnosed genitourinary malignancy. Previously, bio-molecular alterations have been observed within certain locations such as chromosome 9, retinoblastoma gene and fibroblast growth factor receptor-3. Solute carrier family 14 member 1 (SLC14A1) gene encodes the type-B urea transporter (UT-B) which facilitates the passive movement of urea across cell membrane, and has recently been related with human malignancies, especially for bladder cancer. Herein, we discussed the SLC14A1 gene and UT-B protein properties, aiming to elucidate the expression behavior of SLC14A1 in human bladder cancer...
June 6, 2017: Clinical & Translational Oncology
journal
journal
41053
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"